ASCO 2023 Update: This year's ASCO conference... - CLL Support
ASCO 2023 Update
You need to be a member of this community to see this post.
Read more about...
4 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO
to second cancers. This ASCO abstract studies second cancers in CLL patients on ibrutinib or...
Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021
trials of BTK inhibitors. In addition, there are new data on BTK inhibitors combined with...
Ibrutinib Slow but steady foreward movement.
for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia...
End of suspense! Here is Dr. Koffman's ASCO 2020 \"Top Pick\" #1!
untreated patients with chronic lymphocytic leukemia (CLL)....
Reporting from ASCO 2019 (yes ASCO, not ASH)
org/2019/11/asco-2019-cll-societys-dr-koffmans-pick-10-cognitive-function-in-cll-or-chronic-lymphocy
Related Posts
- Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
- An Early Look at When CAR-T Therapy Fails Patients With CLL
- CLL Society Dr. Koffman's ASCO 2020 \"Top 12\" Picks #s 12, 11, 10
- Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
